25 results
S-1
EX-10.1
NVTAQ
Invitae Corp
9 Jan 15
IPO registration
12:00am
been a Change in Control or if Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Corporation … , would have a conflict of interest in representing either the Corporation or Indemnitee in an action to determine Indemnitee’s right
8-K
EX-10.3
NVTAQ
Invitae Corp
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
may include a single special counsel acting in multiple jurisdictions, and, in the case of an actual or reasonably perceived conflict of interest … or reasonably perceived conflict of interest where the Indemnified Party affected by such conflict notifies you of the existence of such conflict
8-K
EX-10.1
NVTAQ
Invitae Corp
5 Jul 23
Departure of Directors or Certain Officers
4:53pm
that conflicts with this Agreement or otherwise creates a conflict of interest with Consultant’s Services.
10.Term; Termination. This Agreement is effective
8-K
EX-10.2
NVTAQ
Invitae Corp
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect
8-K
EX-10.2
NVTAQ
Invitae Corp
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
to such person or (C) in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person
425
typb6p7
24 Jun 20
Business combination disclosure
5:11pm
8-K
EX-10.2
l8qbd
7 Nov 18
Invitae Reports 106% Annual Revenue Growth Driven by 95% Annual Growth in Volume
4:14pm
8-K
EX-10.1
b3oa3 s9mcmu9vap6qoq
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-2.1
lxdjs znwz6w
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-10.3
fpnhobs1nobhy wk
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
PRE 14A
dwc2rbp46tq4o
4 Apr 22
Preliminary proxy
4:15pm
10-K
wi8h ymnd9y
30 Mar 15
Annual report
12:00am